Patient Right to Know Drug Prices Act
This bill became law
What it doesSummary public law (Oct 10, 2018)
Patient Right to Know Drug Prices Act
(Sec. 2) This bill amends the Public Health Service Act to prohibit a health insurance plan or pharmacy benefits manager from restricting a pharmacy from informing an enrollee of any difference between the out-of-pocket cost of a drug under the plan and the cost of the drug without health insurance coverage. (Such restrictions are commonly referred to as gag clauses.)
(Sec. 3) The bill also amends the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to apply certain antitrust filing requirements for generic drug applicants to biosimilar biological product applicants. (Biosimilar biological products, commonly referred to as biosimilars, are biological products approved by the Food and Drug Administration based on their similarity to an already-approved biological product.) Under current law, generic drug applicants that make agreements with brand name drug companies or other generic drug applicants regarding the manufacture, marketing, or sale of their drugs must file such agreements with the Federal Trade Commission and the Department of Justice. The bill subjects biosimilar biological product applicants to the same filing requirements.
What just happenedOct 10, 2018
Became Public Law No: 115-263.
Who’s behind it
- Engrossed in SenateSep 17, 2018
- Reported to SenateJul 31, 2018
- Introduced in SenateMar 14, 2018
- Public LawOct 11, 2018
- Oct 10, 2018President
Became Public Law No: 115-263.
- Oct 10, 2018BecameLaw36000
Became Public Law No: 115-263.
- Oct 10, 2018President
Signed by President.
- Oct 10, 2018BecameLaw36000
Signed by President.
- Oct 1, 2018Floor
Presented to President.
- Oct 1, 2018President28000
Presented to President.
- Sep 25, 2018FloorH38310
Motion to reconsider laid on the table Agreed to without objection.
- Sep 25, 2018FloorH37300
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H8795-8796)
- Sep 25, 2018Floor8000
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H8795-8796)
- Sep 25, 2018FloorH8D000
DEBATE - The House proceeded with forty minutes of debate on S. 2554.
- Sep 25, 2018FloorH30000
Considered under suspension of the rules. (consideration: CR H8795-8799)
- Sep 25, 2018FloorH30300
Mr. Carter (GA) moved to suspend the rules and pass the bill.
- Sep 20, 2018FloorH15000
Held at the desk.
- Sep 20, 2018FloorH14000
Received in the House.
- Sep 18, 2018Floor
Message on Senate action sent to the House.
- Sep 17, 2018Floor
Passed Senate with an amendment by Yea-Nay Vote. 98 - 2. Record Vote Number: 209.
- Sep 17, 2018Floor17000
Passed/agreed to in Senate: Passed Senate with an amendment by Yea-Nay Vote. 98 - 2. Record Vote Number: 209.
- Sep 17, 2018Floor
Measure laid before Senate by unanimous consent. (consideration: CR S6179-6180)
- Jul 31, 2018Calendars
Placed on Senate Legislative Calendar under General Orders. Calendar No. 549.
- Jul 31, 2018Committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
Health, Education, Labor, and Pensions Committee - Jul 31, 2018Committee14000
Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
Health, Education, Labor, and Pensions Committee - Jul 25, 2018Committee
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Health, Education, Labor, and Pensions Committee - Mar 14, 2018IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Mar 14, 2018IntroReferral10000
Introduced in Senate